CA3051840A1 - Cancer therapeutic - Google Patents

Cancer therapeutic Download PDF

Info

Publication number
CA3051840A1
CA3051840A1 CA3051840A CA3051840A CA3051840A1 CA 3051840 A1 CA3051840 A1 CA 3051840A1 CA 3051840 A CA3051840 A CA 3051840A CA 3051840 A CA3051840 A CA 3051840A CA 3051840 A1 CA3051840 A1 CA 3051840A1
Authority
CA
Canada
Prior art keywords
inhibitor
inhibitors
hydroxy
patient
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3051840A
Other languages
English (en)
French (fr)
Inventor
Paul Frank Davis
Tinte Itinteang
Reginald Walter MARSH
Swee Thong Tan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gillies Mcindoe Research Institute
Original Assignee
Gillies Mcindoe Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gillies Mcindoe Research Institute filed Critical Gillies Mcindoe Research Institute
Publication of CA3051840A1 publication Critical patent/CA3051840A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3051840A 2017-01-31 2018-01-31 Cancer therapeutic Pending CA3051840A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762452479P 2017-01-31 2017-01-31
US62/452,479 2017-01-31
PCT/NZ2018/050006 WO2018143826A1 (en) 2017-01-31 2018-01-31 Cancer therapeutic

Publications (1)

Publication Number Publication Date
CA3051840A1 true CA3051840A1 (en) 2018-08-09

Family

ID=63040946

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3051840A Pending CA3051840A1 (en) 2017-01-31 2018-01-31 Cancer therapeutic

Country Status (7)

Country Link
US (2) US20200197335A1 (enExample)
EP (1) EP3576746A4 (enExample)
JP (2) JP2020515523A (enExample)
CN (1) CN110494142A (enExample)
AU (2) AU2018215857A1 (enExample)
CA (1) CA3051840A1 (enExample)
WO (1) WO2018143826A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020027665A1 (en) * 2018-07-30 2020-02-06 Gillies Mcindoe Research Institute Novel pharmaceutical compositions for cancer therapy
WO2020135920A1 (en) * 2018-12-28 2020-07-02 Université Libre de Bruxelles Kit for inhaled chemotherapy, and treatment of lung cancer with said kit
CA3166161A1 (en) * 2020-01-29 2021-08-05 Paul Frank Davis Methods and compositions for the treatment of hemangioma
US20240180852A1 (en) * 2021-03-03 2024-06-06 Signpath Pharma, Inc. Treatment for malignant pleural effusion in humans
CN113069443A (zh) * 2021-04-12 2021-07-06 四川大学 奈必洛尔在制备预防和/或治疗口腔白斑及口腔鳞状细胞癌的药物中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070093457A1 (en) * 2004-02-11 2007-04-26 Nadir Arber Compositions for treatment of cancer and inflammation with curcumin and at least one nsaid
US20170128417A1 (en) * 2014-07-01 2017-05-11 Vicus Therapeutics, Llc Combination drug therapies for cancer and methods of making and using them
MX2017001954A (es) * 2014-08-12 2017-08-14 Gillies Mcindoe Res Inst Diagnostico y terapia del cancer.
WO2016054511A1 (en) * 2014-10-02 2016-04-07 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors for prevention of aging-associated dysfunction of stem cells

Also Published As

Publication number Publication date
US20200197335A1 (en) 2020-06-25
EP3576746A1 (en) 2019-12-11
US20230364037A1 (en) 2023-11-16
WO2018143826A1 (en) 2018-08-09
AU2024200098A1 (en) 2024-01-25
JP2023075272A (ja) 2023-05-30
CN110494142A (zh) 2019-11-22
AU2018215857A1 (en) 2019-08-15
JP2020515523A (ja) 2020-05-28
EP3576746A4 (en) 2020-09-09

Similar Documents

Publication Publication Date Title
US20230364037A1 (en) Cancer therapeutic
JP6195384B2 (ja) 乳癌の処置方法
JP2020122015A (ja) 併用療法
JP6337170B2 (ja) ネコの全身性疾患の予防又は治療の為のアンジオテンシンｉｉ受容体アンタゴニスト
JP6833816B2 (ja) 骨髄腫を治療するためのセルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）
AU2016285597A1 (en) Combination of HDAC inhibitor and anti-PD-L1 antibody for treatment of cancer
US20250090514A1 (en) Method of treating cancer
KR20240104138A (ko) 니로가세스타트를 사용한 조성물 및 치료
WO2020027665A1 (en) Novel pharmaceutical compositions for cancer therapy
NZ796238A (en) Cancer therapeutic
CN115379838A (zh) 包含苯并咪唑衍生物化合物的药物组合物
AU2020327022B2 (en) Method of treating cancer
US20250339442A1 (en) Methods of treatment using a dual specificity tyrosine-phosphorylation-regulated kinase 1a (dyrk1a) inhibitor
US20240165114A1 (en) TREATMENT OF DIABETIC NEPHROPATHY WITH AN sGC STIMULATOR
ES2770785T3 (es) Terapia de combinación
EA049916B1 (ru) Способ предупреждения пептической язвы путем введения фармацевтической композиции, содержащей тегопразан, и применение указанной фармацевтической композиции
EA049014B1 (ru) Способ лечения рака

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230117

EEER Examination request

Effective date: 20230117

EEER Examination request

Effective date: 20230117

EEER Examination request

Effective date: 20230117